Man Group PLC Nuvation Bio Inc. Transaction History

Man Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $386,104 - $552,219	-149,653 Reduced 57.5%	110,626 $323,000
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $32,045 - $87,137	21,949 Added 9.21%	260,279 $947,000
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $228,796 - $364,644	238,330 New	238,330 $359,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $348 - $4,848	1,200 Added 2.23%	55,100 $123,000
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $127,656 - $230,490	39,400 Added 271.72%	53,900 $175,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $66,700 - $128,035	14,500 New	14,500 $76,000

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.